Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase EARLY_PHASE1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 1

Conditions

Mesothelioma, Malignant 2Severe combined immunodeficiency with sensitivity to ionizing radiation 1Pancreatic Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × amatuximab × Clear all
NCT00738582 2022-09-22

Amatuximab

Morphotek

Phase 2 Completed
89 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

NCT00570713 2015-09-09

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Morphotek

Phase 2 Completed
155 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡